Right Ventricular Pulmonary Coupling As a Therapeutic Target in Heart Failure With Preserved Ejection Fraction

Overview

Journal Circ Res

Specialty Cardiology & Vascular Diseases

Date 2019 Jan 18

PMID 30653431

Authors

Thomas R Cimato

John M Canty Jr

Affiliations

Soon will be listed here.

References

Pitt B, Pfeffer M, Assmann S, Boineau R, Anand I, Claggett B . Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014; 370(15):1383-92. DOI: 10.1056/NEJMoa1313731. View

Reddy Y, Obokata M, Koepp K, Egbe A, Wiley B, Borlaug B . The β-Adrenergic Agonist Albuterol Improves Pulmonary Vascular Reserve in Heart Failure With Preserved Ejection Fraction. Circ Res. 2018; 124(2):306-314. PMC: 6336508. DOI: 10.1161/CIRCRESAHA.118.313832. View

Andersen M, Hwang S, Kane G, Melenovsky V, Olson T, Fetterly K . Enhanced pulmonary vasodilator reserve and abnormal right ventricular: pulmonary artery coupling in heart failure with preserved ejection fraction. Circ Heart Fail. 2015; 8(3):542-50. DOI: 10.1161/CIRCHEARTFAILURE.114.002114. View

Pandey A, Garg S, Khunger M, Garg S, Kumbhani D, Chin K . Efficacy and Safety of Exercise Training in Chronic Pulmonary Hypertension: Systematic Review and Meta-Analysis. Circ Heart Fail. 2015; 8(6):1032-43. DOI: 10.1161/CIRCHEARTFAILURE.115.002130. View

Redfield M . Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2016; 375(19):1868-1877. DOI: 10.1056/NEJMcp1511175. View

Borlaug B, Melenovsky V, Koepp K . Inhaled Sodium Nitrite Improves Rest and Exercise Hemodynamics in Heart Failure With Preserved Ejection Fraction. Circ Res. 2016; 119(7):880-6. PMC: 5026595. DOI: 10.1161/CIRCRESAHA.116.309184. View

Lewis G, Schelbert E, Williams S, Cunnington C, Ahmed F, McDonagh T . Biological Phenotypes of Heart Failure With Preserved Ejection Fraction. J Am Coll Cardiol. 2017; 70(17):2186-2200. DOI: 10.1016/j.jacc.2017.09.006. View

Lohse M, Engelhardt S, Danner S, Bohm M . Mechanisms of beta-adrenergic receptor desensitization: from molecular biology to heart failure. Basic Res Cardiol. 1996; 91 Suppl 2:29-34. DOI: 10.1007/BF00795359. View

Chapman K, Smith D, Rebuck A, Leenen F . Hemodynamic effects of an inhaled beta-2 agonist. Clin Pharmacol Ther. 1984; 35(6):762-7. DOI: 10.1038/clpt.1984.108. View

10.

Guazzi M, Vicenzi M, Arena R, Guazzi M . Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation. 2011; 124(2):164-74. DOI: 10.1161/CIRCULATIONAHA.110.983866. View

11.

Redfield M, Chen H, Borlaug B, Semigran M, Lee K, Lewis G . Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. 2013; 309(12):1268-77. PMC: 3835156. DOI: 10.1001/jama.2013.2024. View

12.

Borlaug B, Kane G, Melenovsky V, Olson T . Abnormal right ventricular-pulmonary artery coupling with exercise in heart failure with preserved ejection fraction. Eur Heart J. 2016; 37(43):3293-3302. PMC: 8483148. DOI: 10.1093/eurheartj/ehw241. View

13.

Borlaug B, Anstrom K, Lewis G, Shah S, Levine J, Koepp G . Effect of Inorganic Nitrite vs Placebo on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction: The INDIE-HFpEF Randomized Clinical Trial. JAMA. 2018; 320(17):1764-1773. PMC: 6248105. DOI: 10.1001/jama.2018.14852. View

14.

Snyder E, Wong E, Foxx-Lupo W, Wheatley C, Cassuto N, Patanwala A . Effects of an inhaled β2-agonist on cardiovascular function and sympathetic activity in healthy subjects. Pharmacotherapy. 2011; 31(8):748-56. DOI: 10.1592/phco.31.8.748. View